FDA approves a new treatment for primary immunoglobulin A nephropathy
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Voyxact (sibeprenlimab-szsi) injection to reduce proteinuria (protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. …